{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:15:33Z","timestamp":1794863733015,"version":"4.9.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T00:00:00Z","timestamp":1561075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000762","name":"Imperial College Healthcare NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000762","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ken and Mary Minton Chair of Renal Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immunoglobulin-G4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory condition that can affect multiple organs. Despite growing interest in this condition, the natural history and management of IgG4-RD remain poorly understood.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To describe the clinical characteristics, treatment and outcomes of IgG4-RD in a multi-ethnic UK cohort, and investigate its possible association with malignancy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective analysis of case-note and electronic data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cases were identified from sub-specialty cohorts and a systematic search of an NHS trust histopathology database using \u2018IgG4\u2019 or \u2018inflammatory pseudotumour\u2019 as search terms. Electronic records, imaging and histopathology reports were reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 66 identified cases of IgG4-RD showed a similar multi-ethnic spread to the local population of North West London. The median age was 59\u2009years and 71% of patients were male. Presenting symptoms relating to mass effect of a lesion were present in 48% of cases and the mean number of organs involved was 2.4. Total of 10 patients had reported malignancies with 6 of these being haematological. 83% of those treated with steroids had good initial response; however, 50% had relapsing-remitting disease. Rituximab was administered in 11 cases and all achieved an initial serological response. Despite this, seven patients subsequently relapsed after a mean duration of 11\u2009months and four progressed despite treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We report a large UK-based cohort of IgG4-RD that shows no clear ethnic predisposition and a wide range of affected organs. We discuss the use of serum IgG4 concentrations as a disease marker in IgG4-RD, the association with malignant disease and outcomes according to differing treatment regimens.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcz149","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T08:18:46Z","timestamp":1560500326000},"page":"763-769","source":"Crossref","is-referenced-by-count":10,"title":["IgG4-related disease in a multi-ethnic community: clinical characteristics and association with malignancy"],"prefix":"10.1093","volume":"112","author":[{"given":"S X","family":"Poo","sequence":"first","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, London North West Healthcare NHS Trust, Harrow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C S W","family":"Tham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Cairns","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Galliford","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hamdulay","sequence":"additional","affiliation":[{"name":"Department of Medicine, London North West Healthcare NHS Trust, Harrow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jacyna","sequence":"additional","affiliation":[{"name":"Department of Medicine, London North West Healthcare NHS Trust, Harrow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J B","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S P","family":"McAdoo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Roufosse","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Wernig","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J C","family":"Mason","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C D","family":"Pusey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F W K","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J A P","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Imperial College Healthcare NHS Trust, London, UK"},{"name":"Department of Medicine, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,6,21]]},"reference":[{"key":"2019100900585538200_hcz149-B1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1056\/NEJM200103083441005","article-title":"High serum IgG4 concentrations in patients with sclerosing pancreatitis","volume":"344","author":"Hamano","year":"2001","journal-title":"NEJM"},{"key":"2019100900585538200_hcz149-B2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(02)08359-9","article-title":"Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis","volume":"359","author":"Hamano","year":"2002","journal-title":"Lancet"},{"key":"2019100900585538200_hcz149-B3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1007\/s00535-003-1175-y","article-title":"A new clinicopathological entity of IgG4-related autoimmune disease","volume":"38","author":"Kamisawa","year":"2003","journal-title":"J Gastroenterol"},{"key":"2019100900585538200_hcz149-B4","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1097\/MD.0000000000000680","article-title":"IgG4-related disease: dataset of 235 consecutive patients","volume":"94","author":"Inoue","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2019100900585538200_hcz149-B5","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-Related Disease: baseline clinical and laboratory features in 125 patients with biopsy-proven disease","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2019100900585538200_hcz149-B6","doi-asserted-by":"crossref","first-page":"e1275.","DOI":"10.1097\/MD.0000000000001275","article-title":"IgG4-related disease: results from a multicenter Spanish registry","volume":"94","author":"Fern\u00e1ndez-Codina","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"2019100900585538200_hcz149-B7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009742.2015.1055796","article-title":"IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients","volume":"45","author":"Campochiaro","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"2019100900585538200_hcz149-B8","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"key":"2019100900585538200_hcz149-B9","doi-asserted-by":"crossref","first-page":"e0183844","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PLoS One"},{"key":"2019100900585538200_hcz149-B10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2019100900585538200_hcz149-B11","year":"2011"},{"key":"2019100900585538200_hcz149-B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"Stone","year":"2012","journal-title":"N Engl J Med"},{"key":"2019100900585538200_hcz149-B13","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40266-018-0534-6","article-title":"IgG4-Related Disease: Beyond Glucocorticoids","volume":"35","author":"Akiyama","year":"2018","journal-title":"Drugs Aging"},{"key":"2019100900585538200_hcz149-B14","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/ajg.2014.223","article-title":"Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort","volume":"109","author":"Huggett","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2019100900585538200_hcz149-B15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/14397595.2017.1416891","article-title":"Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan","volume":"28","author":"Saeki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2019100900585538200_hcz149-B16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ajg.2016.40","article-title":"Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort","volume":"111","author":"Culver","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2019100900585538200_hcz149-B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/AJCP\/AQX067","article-title":"Atypical IgG4+ plasmacytic proliferations and lymphomas characterization of 11 cases","volume":"148","author":"Bledsoe","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"2019100900585538200_hcz149-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/259408","article-title":"Development of an IgG4-RD responder index","volume":"2012","author":"Carruthers","year":"2012","journal-title":"Int J Rheumatol"},{"key":"2019100900585538200_hcz149-B19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial","volume":"58","author":"Yunyun","year":"2018","journal-title":"Rheumatology"},{"key":"2019100900585538200_hcz149-B20","first-page":"1755","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Am Coll Rheum"},{"key":"2019100900585538200_hcz149-B21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/eye.2014.251","article-title":"Rituximab for the treatment of IgG4- related orbital disease: experience from five cases","volume":"29","author":"Wu","year":"2015","journal-title":"Eye"},{"key":"2019100900585538200_hcz149-B22","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Am Rheum Dis"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcz149\/28928311\/hcz149.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/112\/10\/763\/30121400\/hcz149.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/qjmed\/article-pdf\/112\/10\/763\/30121400\/hcz149.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T00:59:20Z","timestamp":1570582760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/112\/10\/763\/5521407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,21]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,6,21]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcz149","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,6,21]]}}}